Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?

Lung Cancer. 2020 Jul:145:208-210. doi: 10.1016/j.lungcan.2020.05.006. Epub 2020 May 11.

Authors

Vincenzo Di Noia¹, Alessandro D'Aveni², Michela Squadroni², Giordano Domenico Beretta², Giovanni Luca Ceresoli²

Affiliations

¹ Department of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy. Electronic address: [email protected].
² Department of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

COVID-19
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Coronavirus Infections / pathology
Coronavirus Infections / virology
Humans
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lung Neoplasms / virology
Male
Middle Aged
Nivolumab / administration & dosage*
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / pathology
Pneumonia, Viral / virology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Severe acute respiratory syndrome-related coronavirus / pathogenicity

Substances

PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab